Hepatitis E vaccine landscape update 2025

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review highlights progress in hepatitis e vaccine development and its efficacy against severe maternal and immunocompromised risks.

HEV poses significant public health risks, particularly to pregnant women and immunocompromised individuals.
The HEV 239 vaccine is currently the only licensed vaccine, showing strong efficacy and cross-genotype protection.
Current trials aim to establish safety and efficacy in pregnant women and children, addressing urgent data gaps.
Global prequalification by WHO is crucial for ensuring broader access to effective hepatitis E vaccines.

Kim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark